Thursday, August 24, 2023
SK bioscience and Vaxxas have forged a joint development agreement. The collaboration represents a significant advancement in the field of vaccine delivery.
As per the terms of the agreement, SK bioscience is designated to provide the antigen employed in its typhoid conjugate vaccine, known as SKYTyphoid™. This particular vaccine is the result of a collaborative effort between SK bioscience and the International Vaccine Institute (IVI).
By utilising Vaxxas' HD-MAP technology to deliver the typhoid vaccine, the collaboration aims to make immunisation more accessible, efficient, and effective in regions where typhoid fever is a significant health concern.
The partnership aims to address challenges associated with the distribution and administration of vaccines, particularly in low- and middle-income countries where access to healthcare infrastructure may be limited.
Typhoid fever is a serious illness that often affects countries with lower incomes. But using vaccines for typhoid is tough because the vaccines need to work well even when it's really hot or cold. They also should be easy to use without needing a doctor. This partnership with Vaxxas gives a chance to solve these problems.
